EULAR 2025

Interfering on the long run: less difficult-to-treat…

Preventing, delaying or early sufficient treatment of…

IL-17A/IL-17F-inhibiting nanobody as a new molecule in…

TYK2-Inhibitors a new oral treatment option?

Impact of GLP-1 receptor agonists on cardiovascular…

New bispecific antibodies against axSpA?

The IL-17 story continues!

Effect of TNF inhibitors on the risk of cancer…

Impact of biologics on cardiovascular outcome in AS

Sex-specific response on biologics

Connection between pain and disease activity

Cancer reactivation in axSpA patients treated with…

Neue bispezifische Antikörper gegen axSpA?

Zusammenhang von Schmerz und Krankheitsaktivität

Effetti degli inibitori del TNF sul rischio di recidiva…

Die IL-17-Story geht weiter!

Subjektive oder objektive Endpunkte - gibt es eine…

Krebs-Reaktivierung bei mit TNF-Blockern behandelten…

Geschlechtsspezifisches Ansprechen auf Biologika

Impatto degli agonisti del recettore GLP-1 sugli eventi…

TYK2-Inhibitors a new oral treatment option?

Real world data of Adalimumab vs Ixekizumab in PsA

Sexual health in patients with PsA

Sonelokimab - again IL-17 inhibition or new IL-17…

High prevalence of PsA in PsO patients without…

Definitions and prevalence of difficult-to-treat PsA

TYK2: convenient, safe and effective!

MTX+LEF strategy vs MTX alone in PsA

IL-23 stops radiographic progress

Hit hard & early or tight control - two ways to reach…

Difficult-to-treat patients in active PsA

Sonelokimab, a novel IL-17A- and IL-17F-inhibiting…

TYK2-Inhibitoren bei PsA

TYK2: bequem, sicher und auch wirksam!

Definición y prevalencia de la APs difícil de tratar

Hohe Prävalenz von PsA bei PsO-Patienten ohne…

Sonelokimab, a novel IL-17A- and IL-17F-inhibiting…

Hit Hard & Early oder Tight Control - zwei Wege zum…

Santé sexuelle au cours du rhumatisme psoriasique

IL-23 stoppt radiografischen Progress

Sonelokimab - schon wieder IL-17-Inhibition oder neue…

Difficult-to-treat patients in active PsA

Preventing, delaying or early sufficient treatment of…

Interfering on the long run: less difficult-to-treat…

Abatacept in individuals at risk of delevoping RA

Cancer incidence in RA from the JAK-POT study

ILD in rheumatoid arthritis

New treatment options in RA

Prophylactic therapy with abatacept in patients at risk…

Safety of JAKies in RA

Abatacept en individuos en riesgo de desarrollar AR

Cancer incidence in RA from the JAK-POT study

Prophylaktische Therapie mit Abatacept bei Patienten…

Cost-effectiveness of therapeutic drug monitoring

New therapeutic approach for refractory myositis

Combination therapies in immune mediated inflammatory…

Patient history matters: real-world data of infliximab…

Cancer mortality in inflammatory joint diseases

Neuer Therapieansatz für refrakträre Myositis

Cost-effectiveness of therapeutic drug monitoring

Kombinationstherapien bei immunvermittelten…